Evidence map›Paper›PMID 40634459›Full record

ArticleScientific reports2025

The prognostic significance of MMP-8 tissue Immunoexpression in pancreatic ductal adenocarcinoma after neoadjuvant therapy.

Ella Kesti, Annika Eurola, Mirjami Kaasinen, Harri Mustonen, Jaana Hagström, Timo Sorsa, Ari Ristimäki, Hanna Seppänen, Caj Haglund, Malin Sund

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ella Kesti *Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland. ella.kesti@helsinki.fi.
Annika Eurola *Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Mirjami KaasinenDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Harri MustonenDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Jaana HagströmTranslational Cancer Medicine Research Program, University of Helsinki, Helsinki, 00290, Finland.
Timo SorsaDepartment of Oral and Maxillofacial diseases, University of Helsinki, Helsinki University Hospital, Helsinki, 00290, Finland.
Ari RistimäkiDepartment of Pathology, HUS Diagnostic Center, HUSLAB, Helsinki University Hospital and University of Helsinki, Helsinki, 00290, Finland.
Hanna SeppänenDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Caj HaglundDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.
Malin SundDepartment of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, 00290, Finland.

Funding

the Swedish Cancer Society 19 0273the Swedish Research Council 2019-01690
6 · The paper itself

Abstract

Neoadjuvant therapy (NAT) has become increasingly common in pancreatic ductal adenocarcinoma (PDAC). Still, PDAC remains one of the deadliest cancers and clinically useful biomarkers are needed. Matrix metalloproteinase 8 (MMP-8) has previously been identified as a potential biomarker for PDAC patients undergoing up-front surgery. We investigated the prognostic significance of MMP-8 in PDAC patients treated with NAT and evaluated the association of MMP-8 expression to treatment response. We studied MMP-8 expression using immunohistochemistry in a tissue microarray with samples from 115 NAT and 144 up-front surgery patients. We examined NAT response from resection specimens by estimating the amount of residual tumour cells. We analysed the association of MMP-8 immunoexpression with survival and treatment response. High MMP-8 immunoexpression associated with better survival among patients with strong NAT response (HR 0.22, CI95% 0.05-0.86, p = 0.030). This association was not observed among patients with poor NAT response nor in the overall NAT group. Furthermore, MMP-8 expression did not differ significantly between the NAT and up-front surgery groups. In conclusion, the MMP-8 tissue expression after NAT is a protective biomarker in PDAC patients with strong NAT response but fails to associate with favourable prognosis in patients with poor NAT response.

Indexed as

Carcinoma, Pancreatic DuctalMatrix Metalloproteinase 8Pancreatic NeoplasmsAdultAgedBiomarkers, TumorFemaleHumansImmunohistochemistryMaleMiddle AgedNeoadjuvant TherapyPrognosisBiomarkers, TumorMatrix Metalloproteinase 8MMP8 protein, humanMatrix metalloproteinase 8Neoadjuvant therapyPDAC

Identifiers

PMID40634459
PMCPMC12241335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.